Virucidal activity of SARS-CoV-2 rapid antigen extraction buffers

Since diagnostic sampling material must be considered as infectious, we evaluated whether extraction buffers of SARS-CoV-2 rapid antigen test kits may inactivate SARS-CoV-2. Of concern, seven of nine tested buffers lacked potent virucidal activity. To reduce risk of infection during assay performanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Conzelmann, Carina, Weil, Tatjana, Olari, Lia-Raluca, Gilg, Andrea, Rauch, Lena, Albers, Dan P.J., Groß, Rüdiger, Müller, Janis A., Münch, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711173/
https://www.ncbi.nlm.nih.gov/pubmed/34995991
http://dx.doi.org/10.1016/j.jcv.2021.105062
Descripción
Sumario:Since diagnostic sampling material must be considered as infectious, we evaluated whether extraction buffers of SARS-CoV-2 rapid antigen test kits may inactivate SARS-CoV-2. Of concern, seven of nine tested buffers lacked potent virucidal activity. To reduce risk of infection during assay performance, virucidal antigen extraction buffers that efficiently inactivate virus should replace the extraction buffers in these commercially available point-of-care devices.

Ejemplares similares